CAS: 98323-83-2; Carmoxirole

该化合物是一种化学化合物,属于被称为抗炎剂的药物类别,其主要特点是能够抑制作为炎症反应化合物的丙烯菊酯合成,这是煽动性反应的化合物.这一行动机制使氨氧烃在减轻疼痛和减少炎症方面有效.该化合物通常在各种配方中施用,其药理动力动力学可能涉及吸收,分配,代谢和排泄过程,这是许多药物所共有的.此外,氨氧可产生一系列副作用,根据剂量和个别病人因素而有所不同.通过临床研究评估其安全状况和功效,确保其符合治疗用途的监管标准.与任何制药一样,在开药或使用甲酰素时,必须考虑与其他药物的矛盾和潜在互动.

结构式图片

物理性质

MSDS等安全信息

    上下游产品

    CAS号714950-75-1 2-[α-(4-hydroxy... | CAS号3113-71-1 3-甲基-4-硝基苯甲酸 | CAS号10338-69-9 4-苯基-1,2,3,6-四氢吡啶 | CAS号714950-74-0 3-(3-carboxypro... | CAS号714950-73-9 3-(3-carboxypro... | CAS号714950-72-8 3-(3-carboxypro... | CAS号1011-65-0 吲哚-5-甲酸甲酯 | CAS号115092-81-4 3-(4-氯丁基)-1H-吲哚...

    合成工艺路线路线简述

    • 合成目标产物 3-[4-(3,6-Dihydro-4-Phenyl-1(2H)-Pyridinyl)Butyl]-1H-Indole-5-Carboxylic Acid Hydrochloride 主要起始原料 1H-Indole-5-Carboxylic Acid, 3-[4-(3,6-Dihydro-4-Phenyl-1(2H)-Pyridinyl)Butyl]-, Methyl Ester
    • (文献来源)合成步骤主要原料 1H-Indole-5-Carboxylic Acid, 3-[4-(3,6-Dihydro-4-Phenyl-1(2H)-Pyridinyl)Butyl]-, Methyl Ester
    📜3-(3-Carboxypropyl)-1H-Indole-2,5-Dicarboxylic Acid置于氢氧化钾,红铝,N,N'-羰基二咪唑体系中,用 四氢呋喃,甲苯 作为反应溶剂,化学反应 6.0H,反应生成 3-[4-(3,6-二氢-4-苯基-1(2H)-吡啶)丁基]-1H-吲哚-5-羧酸盐酸盐
    参考文献:吲哚5-羧酸和6-羟基-吲哚-5-羧酸的新合成方法,用于制备维拉唑酮的邻羟基化代谢产物.
    标题:吲哚5-羧酸和6-羟基-吲哚-5-羧酸的新合成方法,用于制备维拉唑酮的邻羟基化代谢产物.
    摘要:在大鼠,狗,猴子和人的肝微粒体中形成的潜在抗抑郁药物维拉唑酮的主要代谢产物是5-氰基-6-羟基-1H-吲哚衍生物.对于水杨基样取代的吲哚的构建,我们采用japp-Klingemann型fischer-吲哚合成规程调整了卡莫西罗的合成.用甲磺酸氯进行羧酸经由羧酰胺的官能团向氰化物的转化.
    DOI:10.1016/j.Bmcl.2004.01.110

    海关参考信息

    专利信息


    专利号:WO-0054773-A1
    优先权日:1999-03-12
    标题:Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
    发明人：GARVEY DAVID S
    权利人:NITROMED INC; GARVEY DAVID S
    摘要:The present invention is directed to novel compositions comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compositions may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antimetic agent, and mixtures thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinaemia or myopia. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL, Pani L. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. Eur J Pharmacol. 2002 Jun 28;447(1):109-14. doi: 10.1016/s0014-2999(02)01896-4. 33(2):76-80. 44 Suppl
    1:S47-9. doi: 10.1007/BF01428393. 111(6):411-6. doi: 10.1111/j.1742-7843.2012.00918.x. Epub 2012 Jul 31. 343(6):588-94. doi: 10.1007/BF00184289. 345(3):300-8. doi: 10.1007/BF00168691. 12(4):387-94. doi: 10.1023/a:1007776918751. 15(7):483-90. 13 Suppl D:129-35. doi: 10.1093/eurheartj/13.suppl_d.129.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知